This is currently changing and will continue to be the focus of further approval studies of newly established drugs, such as the recently published data on trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases [38] or also the treatment with tucatinib as part of the HER2CLIMB study [39]. Here, ERBB2 is linked to breast carcinoma.